Top Markets
Coin of the day
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
Classifica tra le azioni #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Prezzo delle azioni
$15.31
Ultima sincronizzazione: 2024-02-29
Capitalizzazione di mercato
$45.70M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Icosavax, Inc. (ICVX)

Categoria

Storico del prezzo dell'azione per Icosavax, Inc. (ICVX)
Prezzo di chiusura più alto: $15.31 il 2024-02-01

Prezzo di chiusura più basso: $29.91 il 2021-07-01
Storico del prezzo dell'azione di Icosavax, Inc. dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 10.83%
2023 104.14%
2022 -70.48%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$539.14 35.65%
US
$1.04K 56.21%
NL
$120.74 -16.83%
AU
$761.87 8.65%
CH
$130.43 397.46%
US